BRAF and thyroid gland undifferentiated (anaplastic) carcinoma: In addition, as a type III allosteric, non-ATP competitive, and highly selective inhibitor of MEK1/2, trametinib has been approved by the FDA for the treatment of several BRAF V600E-mutated cancers, including metastatic non-small cell lung cancer, metastatic melanoma (in combination with dabrafenib), and locally advanced or metastatic anaplastic thyroid cancer [58].